By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Life Care NewsLife Care NewsLife Care News
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
Search
Technology
  • Advertise
  • Advertise
Health
Entertainment
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved.
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Reading: Recce Pharmaceuticals Granted Australia Patent for RECCE Anti-Infectives
Share
Notification Show More
Font ResizerAa
Life Care NewsLife Care News
Font ResizerAa
  • Education
  • Automobile
  • Entertainment
  • News
  • Tech
  • Sports
Search
  • Home
  • Home
    • Home 1
    • Default Home 5
  • Categories
  • Categories
    • Tech
    • Entertainment
    • Automobile
    • Sports
    • Education
    • News
    • Health
  • Bookmarks
  • Bookmarks
  • More Foxiz
    • Sitemap
  • More Foxiz
    • Sitemap
Follow US
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Health

Recce Pharmaceuticals Granted Australia Patent for RECCE Anti-Infectives

GlobeNews Wire
Last updated: 27/11/2024 6:54 PM
GlobeNews Wire
Share
4 Min Read
Recce Pharmaceuticals Granted Australia Patent for RECCE Anti-Infectives
SHARE
Recce Pharmaceuticals Granted Australia Patent for RECCE Anti-Infectives

November 27, 2024 08:00 ET | Source: Recce Pharmaceuticals

SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, today announced the Australian Patent Office has formally granted Recce a family three patent for its anti-infectives, with expiry in 2037.

“We are thrilled by the Australian Patent Office’s formal recognition of the ground-breaking potential of Recce’s New Class of Anti-Infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals. “The granting of Patent Family 3 solidifies our global intellectual property portfolio, providing protection for R327 and R529 across all major pharmaceutical markets until 2037. This milestone underscores our commitment to addressing critical viral threats with innovative therapies and ensures we are well-positioned to deliver meaningful solutions for patients worldwide.”

The Australian Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), including:

  • Process for the manufacture of RECCE® anti-infectives and a copolymer made by the claimed process.
  • Use of R327 or R529 for the treatment of infections
  • Methods of administration of R327 or R529 by oral, injection, inhalation, and transdermal dose applications

This is the final of Recce’s wholly owned patents granted for family three and the final patent to be granted in Australia, with the Company now patent protected in all major pharmaceutical markets globally.

Filed Expiry Status
Australia 2037 Granted
China 2037 Granted
USA 2037 Granted
Europe 2037 Granted
Germany 2037 Granted
Spain 2037 Granted
France 2037 Granted
UK 2037 Granted
Italy 2037 Granted
Sweden 2037 Granted
Japan 2037 Granted
Hong Kong 2037 Granted


About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.

Corporate Contact
James Graham
Recce Pharmaceuticals Ltd
+61 (02) 9256 2571
James.graham@recce.com.au

Media & Investor Relations (AU)
Andrew Geddes
Seed Media
+61 (02) 9267 4511
andrew@seedmedia.com.au

Media (USA)
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com

Investor Relations (USA & EU)
Guillame van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com

You Might Also Like

GEP PLACED IN THE LEADERS QUADRANT IN GARTNER 2025 MAGIC QUADRANT FOR SOURCE-TO-PAY SUITES

Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th

Strengthening the Sword Arm of the Nation

The Fashion Installation Show by Radico Khaitan: A hit at AlcoBev India 2025

VERSES Provides Update on Private Placement

TAGGED:announcedanti-infectivesantiinfectivesasxrceaustraliancompanydevelopingexpiryfamilyformalformallyfserqglobegrantedgroundbreakingltdnewswirenovnovemberofficeofficespatentpharmaceuticalsreccerecognitionsourcesydneysyntheticthreethrilledtodayuncategorized

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference
Next Article Radiopharm Achieves Nasdaq Listing of American Depositary Shares Radiopharm Achieves Nasdaq Listing of American Depositary Shares

Stay Connected

FacebookLike
TwitterFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
Google NewsFollow
LinkedInFollow
MediumFollow
- Advertisement -

Latest News

ARKS forays into the world of fragrances with the launch of its debut scent ‘ARKS Day’
ARKS forays into the world of fragrances with the launch of its debut scent ‘ARKS Day’
Travel 09/06/2025
Microtech Announces the First U.S. Atrial Microsensor Implantations as Part of its FIH Study
Microtech Announces the First U.S. Atrial Microsensor Implantations as Part of its FIH Study
Health 09/06/2025
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders
Business 09/06/2025
KBRA Releases Research  Private Credit: Business Development Company (BDC) Ratings Compendium: First-Quarter 2025
KBRA Releases Research Private Credit: Business Development Company (BDC) Ratings Compendium: First-Quarter 2025
Business 09/06/2025
//

We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Quick Link

  • About Us
  • Contact Us
  • Editorial Guidelines
  • Privacy Policy
  • Terms and Conditions

Top Categories

  • Automobile
  • Education
  • Entertainment
  • Health
  • News
  • Sports
  • Tech

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

Life Care NewsLife Care News
Follow US
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..

Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?